You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFluticasone furoate
Accession NumberDB08906
TypeSmall Molecule
GroupsApproved
DescriptionFluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. Despite the similarity in the names, fluticasone furoate and fluticasone propionate are different drugs with different properties. It is marketed under the brand name, Veramyst in the US by GlaxoSmithKline for the management of chronic obstructive pulmonary disease (COPD). FDA approved on April 27, 2007. Fluticasone furoate is available as a combination product with vilanterol, a long-acting beta-2 agonist, under the tradename Breo Ellipta. Approved by the FDA in 2013, its use is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease.
Structure
Thumb
Synonyms
Fluticasonum furoas
Furoate de fluticasone
Furoato de fluticasona
External Identifiers
  • GSK 685698
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Arnuity ElliptaPowder200 mcgOral; Respiratory (inhalation)Glaxosmithkline Inc2015-12-14Not applicableCanada
Arnuity ElliptaPowder100 ug/1Respiratory (inhalation)Glaxo Smith Kline Llc2014-08-20Not applicableUs
Arnuity ElliptaPowder200 ug/1Respiratory (inhalation)Glaxo Smith Kline Llc2014-08-20Not applicableUs
Arnuity ElliptaPowder100 mcgOral; Respiratory (inhalation)Glaxosmithkline Inc2016-01-26Not applicableCanada
AvamysSpray, suspension27.5 micrograms/sprayIntrasinalGlaxo Group Limited2008-01-11Not applicableEu
AvamysSpray, suspension27.5 micrograms/sprayIntrasinalGlaxo Group Limited2008-01-11Not applicableEu
AvamysSpray, metered27.5 mcgNasalGlaxosmithkline Inc2007-10-22Not applicableCanada
AvamysSpray, suspension27.5 micrograms/sprayIntrasinalGlaxo Group Limited2008-01-11Not applicableEu
VeramystSpray, metered27.5 ug/1NasalLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2007-05-15Not applicableUs
VeramystSpray, metered27.5 ug/1NasalREMEDYREPACK INC.2013-06-07Not applicableUs
VeramystSpray, metered27.5 ug/1NasalGlaxo Smith Kline Llc2007-05-15Not applicableUs
VeramystSpray, metered27.5 ug/1NasalPhysicians Total Care, Inc.2010-09-07Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlisadeSpray, suspension27.5 micrograms/sprayIntrasinalGlaxo Group Ltd.2008-10-062011-10-09Eu
AlisadeSpray, suspension27.5 micrograms/sprayIntrasinalGlaxo Group Ltd.2008-10-062011-10-09Eu
AlisadeSpray, suspension27.5 micrograms/sprayIntrasinalGlaxo Group Ltd.2008-10-062011-10-09Eu
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Breo ElliptaGlaxosmithkline Inc
SaltsNot Available
Categories
UNIIJS86977WNV
CAS number397864-44-7
WeightAverage: 538.576
Monoisotopic: 538.163693965
Chemical FormulaC27H29F3O6S
InChI KeyXTULMSXFIHGYFS-VLSRWLAYSA-N
InChI
InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1
IUPAC Name
(1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-difluoro-14-{[(fluoromethyl)sulfanyl]carbonyl}-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-14-yl furan-2-carboxylate
SMILES
[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[[email protected]](O)[C@@]1(F)[C@@]2([H])C[[email protected]](F)C2=CC(=O)C=C[C@]12C
Pharmacology
IndicationFluticasone furoate nasal spray is indicated for the treatment of the symptoms of seasonal and perennial allergic rhinitis in patients aged 2 years and older. Breo Ellipta, a mixture of fluticasone furoate and vilanterol is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease. Breo Ellipta should not be used for the relief of acute symptoms of asthma or COPD.
Structured Indications
PharmacodynamicsFluticasone furoate binds to human glucocorticoid receptor more potently than dexamethasone (29.9-times) and fluticasone propionate (1.7-times). It also is highly retained in respiratory tissue. The significance of this finding is that fluticasone furoate may have a more pronounced and prolonged anti-inflammatory effect, which allows for once-daily dosing. It does not have any effect on the QTc interval. Furthermore, fluticasone furoate was not found to affect the hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma.
Mechanism of actionFluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. The precise mechanism through which fluticasone furoate affects rhinitis symptoms is not known. Corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. Specific effects of fluticasone furoate demonstrated in in vitro and in vivo models included activation of the glucocorticoid response element, inhibition of pro-inflammatory transcription factors such as NFkB, and inhibition of antigen-induced lung eosinophilia in sensitized rats. Fluticasone is also found to increase airway retention of long-acting beta adrenergic agonist, thus potentiating its beneficial effects for the treatment of asthma.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glucocorticoid receptorProteinyes
agonist
HumanP04150 details
Related Articles
AbsorptionFollowing intranasal administration of fluticasone furoate, most of the dose is eventually swallowed and undergoes incomplete absorption and extensive first-pass metabolism in the liver and gut, resulting in negligible systemic exposure. Even at the highest recommended intranasal dose of 110 mcg once daily, plasma concentrations were not quantifiable. This is an especially useful feature as it lowers the incidence of adverse events associated with corticosteroid use. If administered using oral solution and intravenous dosing, 30% of the drug is absorbed and rapidly cleared from the plasma. Absolute bioavailability, intranasal route = 0.5%; Absolute bioavailability, oral route = 1.26%; Mean lung absorption time = 7 hours (regardless of formulation);
Volume of distribution

Steady state, IV administration = 608 L

Protein binding>99% protein bound.
Metabolism

Fluticasone furoate does not undergo cleavage into its two separate components, fluticasone and the furoate moiety. It undergoes extensive hepatic metabolism via CYP3A4. The principal route of metabolism is hydrolysis of the S-fluoromethyl carbothioate function to form the inactive 17β-carboxylic acid metabolite. Studies suggest that enterocytes may be involved in the metabolism of unabsorbed drug.

Route of eliminationFluticasone furoate and its metabolites are eliminated primarily in the feces, accounting for approximately 101% and 90% of the orally and intravenously administered dose, respectively. Urinary excretion accounted for approximately 1% and 2% of the orally and intravenously administered dose, respectively. Fluticasone furoate is extensively metabolized so very little is excreted unchanged.
Half lifeElimination phase half-life, IV dose = 15.1 hours; Elimination phase half-life, inhaled = 17 - 24 hours;
Clearance

Total plasma clearance = 58.7 L/h

ToxicityThe most common adverse reactions (>1% incidence) included headache, epistaxis, pharyngolaryngeal pain, nasal ulceration, back pain, pyrexia, and cough.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fluticasone furoate.Approved
AcetaminophenThe serum concentration of Fluticasone furoate can be increased when it is combined with Acetaminophen.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Fluticasone furoate.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluticasone furoate.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Fluticasone furoate.Approved
AfatinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinFluticasone furoate may decrease the antineoplastic activities of Aldesleukin.Approved
AldosteroneThe serum concentration of Fluticasone furoate can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Fluticasone furoate can be increased when it is combined with Alfentanil.Approved, Illicit
ALT-110The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with ALT-110.Investigational
Aluminum hydroxideThe bioavailability of Fluticasone furoate can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of Fluticasone furoate can be decreased when combined with Aluminum phosphate.Approved
AmantadineThe serum concentration of Fluticasone furoate can be increased when it is combined with Amantadine.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Ambenonium.Approved
Aminohippuric acidThe serum concentration of Fluticasone furoate can be increased when it is combined with Aminohippuric acid.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fluticasone furoate.Approved
AmiodaroneThe metabolism of Fluticasone furoate can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Fluticasone furoate can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Fluticasone furoate can be increased when it is combined with Amlodipine.Approved
Amphotericin BFluticasone furoate may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Fluticasone furoate can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Fluticasone furoate can be increased when it is combined with Amsacrine.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fluticasone furoate.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fluticasone furoate.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Fluticasone furoate.Approved, Investigational
AprepitantThe serum concentration of Fluticasone furoate can be increased when it is combined with Aprepitant.Approved, Investigational
AstemizoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Fluticasone furoate can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Fluticasone furoate can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Fluticasone furoate can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Fluticasone furoate can be increased when it is combined with Atorvastatin.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Fluticasone furoate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluticasone furoate.Withdrawn
AzelastineThe serum concentration of Fluticasone furoate can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Fluticasone furoate can be increased when it is combined with Azithromycin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluticasone furoate.Approved, Investigational
BazedoxifeneThe serum concentration of Fluticasone furoate can be increased when it is combined with Bazedoxifene.Approved, Investigational
BendroflumethiazideFluticasone furoate may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fluticasone furoate.Withdrawn
BenzocaineThe serum concentration of Fluticasone furoate can be increased when it is combined with Benzocaine.Approved
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Fluticasone furoate.Approved
BepridilThe serum concentration of Fluticasone furoate can be increased when it is combined with Bepridil.Approved, Withdrawn
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Fluticasone furoate.Investigational
BexaroteneThe serum concentration of Fluticasone furoate can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Fluticasone furoate can be increased when it is combined with Biperiden.Approved
Bismuth SubcitrateThe bioavailability of Fluticasone furoate can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe metabolism of Fluticasone furoate can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Fluticasone furoate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Fluticasone furoate can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Bosutinib.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluticasone furoate.Approved
BromocriptineThe serum concentration of Fluticasone furoate can be increased when it is combined with Bromocriptine.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fluticasone furoate.Investigational
BumetanideFluticasone furoate may increase the hypokalemic activities of Bumetanide.Approved
BuprenorphineThe serum concentration of Fluticasone furoate can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Fluticasone furoate can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Fluticasone furoate can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Fluticasone furoate can be increased when it is combined with Caffeine.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluticasone furoate.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Fluticasone furoate can be decreased when combined with Calcium carbonate.Approved
CanagliflozinThe serum concentration of Fluticasone furoate can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Fluticasone furoate can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Fluticasone furoate can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Fluticasone furoate can be increased when combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Fluticasone furoate.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Fluticasone furoate can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Fluticasone furoate can be increased when it is combined with Caspofungin.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fluticasone furoate.Experimental
CDX-110The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fluticasone furoate.Approved, Investigational
CeritinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Ceritinib.Approved
ChloroquineThe serum concentration of Fluticasone furoate can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideFluticasone furoate may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Fluticasone furoate can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorpromazineThe serum concentration of Fluticasone furoate can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Fluticasone furoate can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Fluticasone furoate can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneFluticasone furoate may increase the hypokalemic activities of Chlorthalidone.Approved
CholesterolThe serum concentration of Fluticasone furoate can be increased when it is combined with Cholesterol.Experimental
CholestyramineCholestyramine can cause a decrease in the absorption of Fluticasone furoate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cholic AcidThe serum concentration of Fluticasone furoate can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Fluticasone furoate can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Fluticasone furoate can be decreased when it is combined with Cimetidine.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Fluticasone furoate can be increased when it is combined with Citalopram.Approved
ClarithromycinThe metabolism of Fluticasone furoate can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Fluticasone furoate can be decreased when combined with Clemastine.Approved
ClofazimineThe serum concentration of Fluticasone furoate can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Fluticasone furoate can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Fluticasone furoate.Approved
ClotrimazoleThe metabolism of Fluticasone furoate can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Fluticasone furoate can be decreased when combined with Cobicistat.Approved
ColchicineThe serum concentration of Fluticasone furoate can be increased when it is combined with Colchicine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Fluticasone furoate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Fluticasone furoate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColforsinThe serum concentration of Fluticasone furoate can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Fluticasone furoate can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Fluticasone furoate can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluticasone furoate.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Coumaphos.Vet Approved
CrizotinibThe metabolism of Fluticasone furoate can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Fluticasone furoate.Investigational
CyclophosphamideThe serum concentration of Fluticasone furoate can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Fluticasone furoate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Fluticasone furoate.Investigational
DabrafenibThe serum concentration of Fluticasone furoate can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Fluticasone furoate can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Fluticasone furoate can be increased when it is combined with Dactinomycin.Approved
DarunavirThe metabolism of Fluticasone furoate can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Fluticasone furoate can be decreased when it is combined with Daunorubicin.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Fluticasone furoate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Fluticasone furoate can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Fluticasone furoate.Investigational
DesipramineThe serum concentration of Fluticasone furoate can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Fluticasone furoate can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Fluticasone furoate can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Fluticasone furoate can be increased when it is combined with Dextromethorphan.Approved
DichlorvosThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Dichlorvos.Vet Approved
DiclofenacThe serum concentration of Fluticasone furoate can be increased when it is combined with Diclofenac.Approved, Vet Approved
DienestrolThe serum concentration of Fluticasone furoate can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Fluticasone furoate can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluticasone furoate.Approved
DigoxinThe serum concentration of Fluticasone furoate can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe metabolism of Fluticasone furoate can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneFluticasone furoate may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe metabolism of Fluticasone furoate can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Dipyridamole.Approved
DonepezilThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Donepezil.Approved
DoxazosinThe serum concentration of Fluticasone furoate can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Fluticasone furoate can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Fluticasone furoate can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Fluticasone furoate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Fluticasone furoate can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Fluticasone furoate can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Fluticasone furoate.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fluticasone furoate.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Fluticasone furoate.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Fluticasone furoate.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Edrophonium.Approved
EfavirenzThe serum concentration of Fluticasone furoate can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Fluticasone furoate can be increased when it is combined with Elbasvir.Approved
EnalaprilThe serum concentration of Fluticasone furoate can be increased when it is combined with Enalapril.Approved, Vet Approved
EnoxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Fluticasone furoate can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Fluticasone furoate.Approved
ErgonovineThe serum concentration of Fluticasone furoate can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Fluticasone furoate can be increased when it is combined with Ergotamine.Approved
ErythromycinThe metabolism of Fluticasone furoate can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Fluticasone furoate can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Fluticasone furoate can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Fluticasone furoate can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Fluticasone furoate can be increased when it is combined with Estrone.Approved
Etacrynic acidFluticasone furoate may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Fluticasone furoate.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Fluticasone furoate can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Fluticasone furoate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fluticasone furoate.Approved
EtoposideThe serum concentration of Fluticasone furoate can be increased when it is combined with Etoposide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluticasone furoate.Approved, Investigational
EtravirineThe serum concentration of Fluticasone furoate can be decreased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Fluticasone furoate.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Fluticasone furoate.Investigational
FelodipineThe serum concentration of Fluticasone furoate can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fluticasone furoate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fluticasone furoate.Approved
FentanylThe serum concentration of Fluticasone furoate can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Fenthion.Vet Approved
FexofenadineThe serum concentration of Fluticasone furoate can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Fluticasone furoate can be increased when it is combined with Fidaxomicin.Approved
FleroxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Fluticasone furoate.Approved, Withdrawn
FluconazoleThe metabolism of Fluticasone furoate can be decreased when combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Fluticasone furoate.Vet Approved
FluoxetineThe serum concentration of Fluticasone furoate can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluoxymesteroneFluticasone furoate may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlupentixolThe serum concentration of Fluticasone furoate can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Fluticasone furoate can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Fluticasone furoate can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fluticasone furoate.Approved, Investigational
FluvoxamineThe metabolism of Fluticasone furoate can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Fluticasone furoate can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Fluticasone furoate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Fluticasone furoate can be increased when combined with Fosphenytoin.Approved
FurosemideFluticasone furoate may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Fluticasone furoate can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Gefitinib.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Fluticasone furoate can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Ginkgo biloba.Approved, Nutraceutical
GlyburideThe serum concentration of Fluticasone furoate can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Fluticasone furoate can be increased when it is combined with Glycerol.Experimental
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Fluticasone furoate.Approved
Gramicidin DThe serum concentration of Fluticasone furoate can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Fluticasone furoate can be increased when it is combined with Haloperidol.Approved
HexestrolThe serum concentration of Fluticasone furoate can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Fluticasone furoate.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Fluticasone furoate.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluticasone furoate.Approved, Investigational
HydrochlorothiazideFluticasone furoate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Fluticasone furoate can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideFluticasone furoate may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fluticasone furoate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Fluticasone furoate.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Fluticasone furoate.Approved
IdelalisibThe serum concentration of Fluticasone furoate can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Fluticasone furoate can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Fluticasone furoate can be increased when it is combined with Imipramine.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Fluticasone furoate.Approved
IndapamideFluticasone furoate may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Fluticasone furoate can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Fluticasone furoate can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fluticasone furoate.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with INGN 225.Investigational
IsavuconazoniumThe metabolism of Fluticasone furoate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Fluticasone furoate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fluticasone furoate.Withdrawn
IsradipineThe metabolism of Fluticasone furoate can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Fluticasone furoate can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Fluticasone furoate can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Fluticasone furoate can be increased when it is combined with Ivermectin.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fluticasone furoate.Experimental
KetamineThe serum concentration of Fluticasone furoate can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe metabolism of Fluticasone furoate can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluticasone furoate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fluticasone furoate.Approved
LansoprazoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Fluticasone furoate.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Fluticasone furoate can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Fluticasone furoate can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Fluticasone furoate can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Fluticasone furoate can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Fluticasone furoate can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluticasone furoate.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Lomefloxacin.Approved
LomitapideThe serum concentration of Fluticasone furoate can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Fluticasone furoate can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Fluticasone furoate can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Fluticasone furoate can be increased when it is combined with Loratadine.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluticasone furoate.Approved
LosartanThe serum concentration of Fluticasone furoate can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Fluticasone furoate can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Loxapine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fluticasone furoate.Approved
LuliconazoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Fluticasone furoate can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Fluticasone furoate.Approved, Investigational
MagaldrateThe bioavailability of Fluticasone furoate can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Fluticasone furoate can be decreased when combined with Magnesium carbonate.Approved
Magnesium hydroxideThe bioavailability of Fluticasone furoate can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Fluticasone furoate can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluticasone furoate.Approved
Magnesium TrisilicateThe bioavailability of Fluticasone furoate can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Malathion.Approved, Investigational
MaprotilineThe serum concentration of Fluticasone furoate can be increased when it is combined with Maprotiline.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fluticasone furoate.Approved
MebendazoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Mebendazole.Approved, Vet Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluticasone furoate.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fluticasone furoate.Approved
MefloquineThe serum concentration of Fluticasone furoate can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Fluticasone furoate can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fluticasone furoate.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Memantine.Approved, Investigational
MeprobamateThe serum concentration of Fluticasone furoate can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluticasone furoate.Approved
MestranolThe serum concentration of Fluticasone furoate can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Fluticasone furoate.Withdrawn
MethadoneThe serum concentration of Fluticasone furoate can be increased when it is combined with Methadone.Approved
MethallenestrilThe serum concentration of Fluticasone furoate can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideFluticasone furoate may increase the hypokalemic activities of Methyclothiazide.Approved
MethyltestosteroneFluticasone furoate may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazoneFluticasone furoate may increase the hypokalemic activities of Metolazone.Approved
MetoprololThe serum concentration of Fluticasone furoate can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Fluticasone furoate can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Fluticasone furoate can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe therapeutic efficacy of Fluticasone furoate can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Minaprine.Approved
MitomycinThe serum concentration of Fluticasone furoate can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Fluticasone furoate can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Fluticasone furoate can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MivacuriumMivacurium may increase the adverse neuromuscular activities of Fluticasone furoate.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluticasone furoate.Investigational
ModafinilThe serum concentration of Fluticasone furoate can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Fluticasone furoate can be increased when it is combined with Morphine.Approved, Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluticasone furoate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluticasone furoate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fluticasone furoate.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluticasone furoate.Investigational
NafcillinThe serum concentration of Fluticasone furoate can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Fluticasone furoate.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Nalidixic Acid.Approved
NaltrexoneThe serum concentration of Fluticasone furoate can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Fluticasone furoate.Approved, Vet Approved
NaringeninThe serum concentration of Fluticasone furoate can be increased when it is combined with Naringenin.Experimental
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Fluticasone furoate.Investigational
NefazodoneThe metabolism of Fluticasone furoate can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Fluticasone furoate can be decreased when combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Nemonoxacin.Investigational
NeostigmineThe serum concentration of Fluticasone furoate can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fluticasone furoate.Approved
NetupitantThe serum concentration of Fluticasone furoate can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Fluticasone furoate can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Fluticasone furoate can be increased when it is combined with Nicardipine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Nicorandil.Approved
NifedipineThe serum concentration of Fluticasone furoate can be decreased when it is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluticasone furoate.Approved
NilotinibThe metabolism of Fluticasone furoate can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluticasone furoate.Approved, Withdrawn
NisoldipineThe serum concentration of Fluticasone furoate can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Fluticasone furoate can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Fluticasone furoate can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fluticasone furoate.Investigational
NorethisteroneThe serum concentration of Fluticasone furoate can be decreased when it is combined with Norethisterone.Approved
NorfloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Ofloxacin.Approved
OlaparibThe metabolism of Fluticasone furoate can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluticasone furoate.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluticasone furoate.Approved
OmeprazoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Fluticasone furoate.Vet Approved
OsimertinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Osimertinib.Approved
OxandroloneFluticasone furoate may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluticasone furoate.Approved
OxymetholoneFluticasone furoate may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluticasone furoate.Withdrawn
P-NitrophenolThe serum concentration of Fluticasone furoate can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Fluticasone furoate can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Fluticasone furoate can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Fluticasone furoate can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Pantoprazole.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Fluticasone furoate.Approved
ParoxetineThe serum concentration of Fluticasone furoate can be increased when it is combined with Paroxetine.Approved, Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Pefloxacin.Approved
PentobarbitalThe metabolism of Fluticasone furoate can be increased when combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe serum concentration of Fluticasone furoate can be increased when it is combined with Perindopril.Approved
PhenobarbitalThe metabolism of Fluticasone furoate can be increased when combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Fluticasone furoate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluticasone furoate.Approved, Vet Approved
PhenytoinThe metabolism of Fluticasone furoate can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluticasone furoate.Approved, Investigational
PimozideThe serum concentration of Fluticasone furoate can be increased when it is combined with Pimozide.Approved
PiretanideFluticasone furoate may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluticasone furoate.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluticasone furoate.Approved, Investigational
Platelet Activating FactorThe serum concentration of Fluticasone furoate can be decreased when it is combined with Platelet Activating Factor.Experimental
Polyestradiol phosphateThe serum concentration of Fluticasone furoate can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideFluticasone furoate may increase the hypokalemic activities of Polythiazide.Approved
PonatinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe metabolism of Fluticasone furoate can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Fluticasone furoate can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Fluticasone furoate can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Fluticasone furoate can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe metabolism of Fluticasone furoate can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Fluticasone furoate can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Fluticasone furoate can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromestrieneThe serum concentration of Fluticasone furoate can be increased when it is combined with Promestriene.Investigational
PromethazineThe serum concentration of Fluticasone furoate can be increased when it is combined with Promethazine.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fluticasone furoate.Approved
PropafenoneThe serum concentration of Fluticasone furoate can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Fluticasone furoate can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Fluticasone furoate can be increased when it is combined with Protriptyline.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Fluticasone furoate.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Pyridostigmine.Approved
QuercetinThe serum concentration of Fluticasone furoate can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Fluticasone furoate can be increased when it is combined with Quinacrine.Approved
QuinestrolThe serum concentration of Fluticasone furoate can be increased when it is combined with Quinestrol.Approved
QuinethazoneFluticasone furoate may increase the hypokalemic activities of Quinethazone.Approved
QuinidineThe serum concentration of Fluticasone furoate can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Fluticasone furoate can be increased when it is combined with Quinine.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Rabies vaccine.Approved
RanitidineThe serum concentration of Fluticasone furoate can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Fluticasone furoate can be increased when it is combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Fluticasone furoate.Withdrawn
ReboxetineThe serum concentration of Fluticasone furoate can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Fluticasone furoate can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Fluticasone furoate can be decreased when it is combined with Reserpine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluticasone furoate.Experimental, Investigational
RifabutinThe metabolism of Fluticasone furoate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Fluticasone furoate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Fluticasone furoate can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Fluticasone furoate can be increased when it is combined with Rilpivirine.Approved
RitonavirThe metabolism of Fluticasone furoate can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Fluticasone furoate.Investigational, Withdrawn
RolapitantThe serum concentration of Fluticasone furoate can be increased when it is combined with Rolapitant.Approved
RosoxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Rosoxacin.Approved
S EquolThe serum concentration of Fluticasone furoate can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluticasone furoate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fluticasone furoate.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluticasone furoate.Approved
SaquinavirThe metabolism of Fluticasone furoate can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Fluticasone furoate can be increased when it is combined with Scopolamine.Approved
SecoisolariciresinolThe serum concentration of Fluticasone furoate can be increased when it is combined with Secoisolariciresinol.Investigational
SelegilineThe serum concentration of Fluticasone furoate can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluticasone furoate.Approved, Investigational
SertralineThe serum concentration of Fluticasone furoate can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Fluticasone furoate can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Fluticasone furoate can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Fluticasone furoate can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Fluticasone furoate can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Fluticasone furoate can be decreased when it is combined with Sirolimus.Approved, Investigational
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Fluticasone furoate.Approved
SorafenibThe serum concentration of Fluticasone furoate can be increased when it is combined with Sorafenib.Approved, Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Sparfloxacin.Approved
SpironolactoneThe serum concentration of Fluticasone furoate can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Fluticasone furoate.Investigational
St. John's WortThe serum concentration of Fluticasone furoate can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololFluticasone furoate may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StaurosporineThe serum concentration of Fluticasone furoate can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Fluticasone furoate can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Fluticasone furoate can be decreased when it is combined with Streptozocin.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluticasone furoate.Approved
SulfinpyrazoneThe serum concentration of Fluticasone furoate can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Fluticasone furoate can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Fluticasone furoate.Approved
SumatriptanThe serum concentration of Fluticasone furoate can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluticasone furoate.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Fluticasone furoate can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Fluticasone furoate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe serum concentration of Fluticasone furoate can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Fluticasone furoate can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Fluticasone furoate can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Fluticasone furoate can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Fluticasone furoate.Approved
TelithromycinThe metabolism of Fluticasone furoate can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Fluticasone furoate can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Temafloxacin.Withdrawn
TemsirolimusThe serum concentration of Fluticasone furoate can be increased when it is combined with Temsirolimus.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fluticasone furoate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Fluticasone furoate.Vet Approved
TerazosinThe serum concentration of Fluticasone furoate can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Fluticasone furoate can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluticasone furoate.Approved
TesmilifeneThe serum concentration of Fluticasone furoate can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Fluticasone furoate can be increased when it is combined with Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluticasone furoate.Approved
TiboloneThe serum concentration of Fluticasone furoate can be increased when it is combined with Tibolone.Approved
TicagrelorThe serum concentration of Fluticasone furoate can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Fluticasone furoate can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fluticasone furoate.Investigational
TocilizumabThe serum concentration of Fluticasone furoate can be decreased when it is combined with Tocilizumab.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluticasone furoate.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluticasone furoate.Approved
TolvaptanThe serum concentration of Fluticasone furoate can be increased when it is combined with Tolvaptan.Approved
TorasemideFluticasone furoate may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluticasone furoate.Approved, Investigational
TrazodoneThe serum concentration of Fluticasone furoate can be decreased when it is combined with Trazodone.Approved, Investigational
TrichlorfonThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Trichlorfon.Vet Approved
TrichlormethiazideFluticasone furoate may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Fluticasone furoate can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Fluticasone furoate can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Fluticasone furoate can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Fluticasone furoate can be increased when it is combined with Trimipramine.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Fluticasone furoate.Approved
TroleandomycinThe serum concentration of Fluticasone furoate can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluticasone furoate.Investigational, Withdrawn
VenlafaxineThe metabolism of Fluticasone furoate can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Fluticasone furoate can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Fluticasone furoate can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Fluticasone furoate can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Fluticasone furoate can be increased when it is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe metabolism of Fluticasone furoate can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinFluticasone furoate may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluticasone furoate.Approved
ZeranolThe serum concentration of Fluticasone furoate can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Fluticasone furoate.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Fluticasone furoate can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Fluticasone furoate can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluticasone furoate.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Adrienne KOVACSNE-MEZEI, Roman Gabriel, Alexandr Jegorov, “POLYMORPHS OF FLUTICASONE FUROATE AND PROCESSES FOR PREPARATION THEREOF.” U.S. Patent US20100240629, issued September 23, 2010.

US20100240629
General References
  1. Allen A, Schenkenberger I, Trivedi R, Cole J, Hicks W, Gul N, Jacques L: Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study. Clin Respir J. 2013 Oct;7(4):397-406. doi: 10.1111/crj.12026. Epub 2013 Jun 5. [PubMed:23578031 ]
  2. Tamm M, Richards DH, Beghe B, Fabbri L: Inhaled corticosteroid and long-acting beta2-agonist pharmacological profiles: effective asthma therapy in practice. Respir Med. 2012 Dec;106 Suppl 1:S9-19. doi: 10.1016/S0954-6111(12)70005-7. [PubMed:23273165 ]
  3. Allen A, Bareille PJ, Rousell VM: Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet. 2013 Jan;52(1):37-42. doi: 10.1007/s40262-012-0021-x. [PubMed:23184737 ]
External Links
ATC CodesR03AK10R01AD12R03BA09
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (469 KB)
MSDSDownload (70.2 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9917
Blood Brain Barrier+0.9666
Caco-2 permeable-0.5222
P-glycoprotein substrateSubstrate0.7675
P-glycoprotein inhibitor IInhibitor0.784
P-glycoprotein inhibitor IIInhibitor0.604
Renal organic cation transporterNon-inhibitor0.8329
CYP450 2C9 substrateNon-substrate0.8023
CYP450 2D6 substrateNon-substrate0.8893
CYP450 3A4 substrateSubstrate0.7205
CYP450 1A2 substrateNon-inhibitor0.6493
CYP450 2C9 inhibitorNon-inhibitor0.7288
CYP450 2D6 inhibitorNon-inhibitor0.8305
CYP450 2C19 inhibitorNon-inhibitor0.6388
CYP450 3A4 inhibitorInhibitor0.9211
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.69
Ames testNon AMES toxic0.747
CarcinogenicityNon-carcinogens0.9079
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6232 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9787
hERG inhibition (predictor II)Non-inhibitor0.566
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Spray, suspensionIntrasinal27.5 micrograms/spray
PowderOral; Respiratory (inhalation)100 mcg
PowderOral; Respiratory (inhalation)200 mcg
PowderRespiratory (inhalation)100 ug/1
PowderRespiratory (inhalation)200 ug/1
Spray, meteredNasal27.5 mcg
PowderRespiratory (inhalation)
Spray, meteredNasal27.5 ug/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5873360 No1996-02-232016-02-23Us
US6537983 No2001-08-032021-08-03Us
US6759398 No2001-08-032021-08-03Us
US6858596 No2001-08-032021-08-03Us
US6878698 No2001-08-032021-08-03Us
US7101866 No2001-08-032021-08-03Us
US7439393 No2002-09-112022-09-11Us
US7541350 No2001-08-032021-08-03Us
US7629335 No2001-08-032021-08-03Us
US7776895 No2002-09-112022-09-11Us
US8062264 No2006-04-052026-04-05Us
US8113199 No2007-10-232027-10-23Us
US8147461 No2008-10-152028-10-15Us
US8161968 No2008-02-052028-02-05Us
US8201556 No2009-02-052029-02-05Us
US8347879 No2008-07-152028-07-15Us
US8511304 No2007-06-142027-06-14Us
US8534281 No2009-08-102029-08-10Us
US8746242 No2010-10-112030-10-11Us
US8752543 No2006-04-052026-04-05Us
USRE44874 No2003-03-232023-03-23Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityInsoluble FDA label
pKa6 FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.0434 mg/mLALOGPS
logP3.73ALOGPS
logP4.13ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)13.56ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area93.81 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity130.08 m3·mol-1ChemAxon
Polarizability51.55 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid esters
Direct ParentSteroid esters
Alternative Parents
Substituents
  • Steroid ester
  • Androgen-skeleton
  • Androstane-skeleton
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • Halo-steroid
  • 6-halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Furoate
  • Heteroaromatic compound
  • Furan
  • Cyclic alcohol
  • Cyclic ketone
  • Thiocarboxylic acid ester
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Fluorohydrin
  • Carboxylic acid ester
  • Oxacycle
  • Organoheterocyclic compound
  • Sulfenyl compound
  • Thioether
  • Thiocarboxylic acid or derivatives
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Halomethane
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Hughes SC, Shardlow PC, Hollis FJ, Scott RJ, Motivaras DS, Allen A, Rousell VM: Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid, in humans. Drug Metab Dispos. 2008 Nov;36(11):2337-44. doi: 10.1124/dmd.108.022137. Epub 2008 Aug 11. [PubMed:18694910 ]
Comments
comments powered by Disqus
Drug created on June 16, 2013 17:03 / Updated on December 04, 2016 02:45